Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy

Journal of Structural Biology

Volumn 176, Issue 3, 2011, Pages 292-301

  Lountos, George T ^a   Jobson, Andrew G ^b   Tropea, Joseph E ^a   Self, Christopher R ^c   Zhang, Guangtao ^c   Pommier, Yves ^b   Shoemaker, Robert H ^a   Waugh, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Provid Pharmaceuticals   (United States)

Author keywords

Crystal structure; Kinase inhibitor; Structure based drug design

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHECKPOINT KINASE 2 INHIBITOR; COMPOUND 53; COMPOUND 63; NSC 109555; PV 1019; PV 1115; PV 1531; PV 1533; PV 788; PV 976; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER THERAPY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 80455122697     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2011.09.008     Document Type: Article

References (65)

1. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60:5934-5936.
2. Ahn J.Y., Li X., Davis H.L., Canman C.E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J. Biol. Chem. 2002, 277:19389-19395.
3. Anderson V.E., Walton M.I., Eve P.D., Boxall K.J., Antoni L., et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011, 71:463-472.
4. Antoni L., Sodha N., Collins I., Garrett M.D. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?. Nat. Rev. Cancer 2007, 7:925-936.
5. Arienti K.L., Brunmark A., Axe F.U., McClure K., Lee A., et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 2005, 48:1873-1885.
6. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
7. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
8. Brunger A.T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355:472-475.
9. Byczkowski J.Z., Porter C.W. Interactions between bis(guanylhydrazones) and polyamines in isolated-mitochondria. Gen. Pharmacol. 1983, 14:615-621.
10. Caldwell J.J., Welsh E.J., Matijssen C., Anderson V.E., Antoni L., et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J. Med. Chem. 2011, 54:580-590.
11. Carlessi L., Buscemi G., Larson G., Hong Z., Wu J.Z., et al. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol. Cancer Ther. 2007, 6:935-944.
12. CCP4 suite, 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763.
13. Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab. Rev. 2002, 34:565-579.
14. Clement B., Burenheide A., Rieckert W., Schwarz J. Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem 2006, 1:1260-1267.
15. Curman D., Cinel B., Williams D.E., Rundle N., Block W.D., et al. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 2001, 276:17914-17919.
16. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
17. Denny W.A., Cain B.F. Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis(guanylhydrazones). J. Med. Chem. 1979, 22:1234-1238.
18. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
19. Foloppe N., Fisher L.M., Francis G., Howes R., Kierstan P., Potter A. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. Bioorg. Med. Chem. 2006, 14:1792-1804.
20. Freiberg R.A., Hammond E.M., Dorie M.J., Welford S.M., Giaccia A.J. DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol. Cell. Biol. 2006, 26:1598-1609.
21. Garrett M.D., Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when?. Trends Pharmacol. Sci. 2011, 32:308-316.
22. Ghosh J.C., Dohi T., Raskett C.M., Kowalik T.F., Altieri D.C. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res. 2006, 66:11576-11579.
23. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
24. Gustafsson D., Nystrom J., Carlsson S., Bredberg U., Eriksson U., et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 2001, 101:171-181.
25. Havemeyer A., Bittner F., Wollers S., Mendel R., Kunze T., et al. Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme. J. Biol. Chem. 2006, 281:34796-34802.
26. Hilton S., Naud S., Caldwell J.J., Boxall K., Burns S., et al. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorg. Med. Chem. 2010, 18:707-718.
27. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000, 287:1824-1827.
28. Hirao A., Cheung A., Duncan G., Girard P.M., Elia A.J., et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 2002, 22:6521-6532.
29. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
30. Janetka J.W., Ashwell S. Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin. Ther. Pat. 2009, 19:165-197.
31. Jobson A.G., Cardellina J.H., Scudiero D., Kondapaka S., Zhang H., et al. Identification of a bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol. Pharmacol. 2007, 72:876-884.
32. Jobson A.G., Lountos G.T., Lorenzi P.L., Llamas J., Connelly J., et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp. Ther. 2009, 331:816-826.
33. Levesque A.A., Eastman A. P53-based cancer therapies: is defective p53 the Achilles heel of the tumor?. Carcinogenesis 2007, 28:13-20.
34. Lountos G.T., Tropea J.E., Zhang D., Jobson A.G., Pommier Y., et al. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci. 2009, 18:92-100.
35. Marcus S.L., Nathan H.C., Hutner S.H., Bacchi C.J. Polyamines antagonize both the antileukemic activity and the reverse-transcriptase stimulatory activity of 4,4'-diacetyldiphenylurea bis(guanylhydrazone) (Ddug). Biochem. Biophys. Res. Commun. 1987, 142:422-427.
36. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
37. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. USA 2000, 97:10389-10394.
38. Minor W., Cymborowski M., Otwinowski Z., Chruszcz M. HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:859-866.
39. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276:955-960.
40. Morao I., Tai Z., Hillier I.H., Burton N.A. What form of N-G-hydroxy-l-arginine is the intermediate in the mechanism of NO synthase? QM and QM/MM calculations of substrate-active site interactions. J. Mol. Struct. - Theochem 2003, 632:277-285.
41. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997, 53:240-255.
42. Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., et al. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 2006, 25:3179-3190.
43. Oliver A.W., Knapp S., Pearl L.H. Activation segment exchange: a common mechanism of kinase autophosphorylation?. Trends Biochem. Sci. 2007, 32:351-356.
44. Poehlmann A., Roessner A. Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol. Res. Pract. 2010, 206:591-601.
45. Pommier Y., Sordet O., Rao V.A., Zhang H., Kohn K.W. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr. Pharm. Des. 2005, 11:2855-2872.
46. Pommier Y., Weinstein J.N., Aladjem M.I., Kohn K.W. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin. Cancer Res. 2006, 12:2657-2661.
47. Read R.J. Model phases: probabilities and bias. Methods Enzymol. 1997, 277:110-128.
48. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 2002, 7:601-611.
49. Schuttelkopf A.W., van Aalten D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:1355-1363.
50. Sharma V., Hupp C.D., Tepe J.J. Enhancement of chemotherapeutic efficacy by small molecule inhibition of NF-kappaB and checkpoint kinases. Curr. Med. Chem. 2007, 14:1061-1074.
51. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6:813-823.
52. Stolz A., Ertych N., Kienitz A., Vogel C., Schneider V., et al. The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat. Cell Biol. 2010, 12:492-U179.
53. Tai A.W., Lien E.J., Moore E.C., Chun Y., Roberts J.D. Studies of N-hydroxy-N'-aminoguanidine derivatives by nitrogen-15 nuclear magnetic resonance spectroscopy and as ribonucleotide reductase inhibitors. J. Med. Chem. 1983, 26:1326-1329.
54. Takai H., Naka K., Okada Y., Watanabe M., Harada N., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 2002, 21:5195-5205.
55. Tan Y., Raychaudhuri P., Costa R.H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. 2007, 27:1007-1016.
56. Toledo L.M., Lydon N.B., Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6:775-805.
57. Vagin A., Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:22-25.
58. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8:127-134.
59. Wu X., Chen J. Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis. J. Biol. Chem. 2003, 278:36163-36168.
60. Yu Q., Rose J.H., Zhang H., Pommier Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 2001, 505:7-12.
61. Yu Q., La Rose J., Zhang H., Takemura H., Kohn K.W., Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 2002, 62:5743-5748.
62. Zhang J., Willers H., Feng Z., Ghosh J.C., Kim S., et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 2004, 24:708-718.
63. Zhou B.B., Sausville E.A. Drug discovery targeting Chk1 and Chk2 kinases. Prog. Cell Cycle Res. 2003, 5:413-421.
64. Zhou B.B., Anderson H.J., Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol. Ther. 2003, 2:S16-S22.
65. Zoppoli, G., Solier, S., Reinghold, W.C., Liu, H., Connelly, J.W. Jr., Monks, A., Shoemaker, R.H., Abaan, O.D., Davis, S.R., Meltzer, P.S., Doroshow, J.H., and Pommier, Y., in press. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene. doi:10.1038/onc.2011.283.